Galectin Therapeutics Granted Interlinked an Exclusive Interview on Galectin Protein Research and Clinical Trials during Recent FSX Investment Conference

Share Article

Galectin Therapeutics granted Interlinked an Exclusive Interview on their leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer during recent FSX Investment Conference

Executive Chairman of Galectin Therapeutics granted Exclusive interview for Interlinked during recent FSX Investment Conference

Executive Chairman of Galectin Therapeutics granted Exclusive interview for Interlinked during recent FSX Investment Conference

We are entering clinical trials right now and recruiting patients for the first drug for fatty liver disease with fibrosis in the history of the world.

At the recent FSX Investment Conference held at the Ritz-Carlton in San Francisco, California, James Czirr, Executive Chairman of Galectin Therapeutics granted an exclusive interview available on Galectin Therapeutics's Public Profile on Interlinked's IDeal Room.

Galectin Therapeutics is a development company that engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. They are applying their leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer.

During the interview Mr. Czirr stated that last year 45% of all deaths in the United States were attributable to some sort of organ failure caused by fibrosis.

He continued to say that they are expecting to report information by the end of June 2013 about the trial being conducted in Belgium by the Ludwig Institute. Mr. Czirr added that Galectin Therapeutics is also entering an FDA sanctioned clinical trial in the United States in the area of Fibrosis.

"We are entering clinical trials right now and recruiting patients for the first drug for fatty liver disease with fibrosis in the history of the world." stated Mr. Czirr.

Watch the complete interview and visit Galectin’s public profile on Interlinked’s IDeal Room for more information https://members.interlinked.com/?c=Galectin

ABOUT GALECTIN THERAPEUTICS
Galectin Therapeutics,(formerly Pro-Pharmaceuticals) is a development-stage company, engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. For more information visit Galectin's Public Profile on Interlinked's IDeal Room.

ABOUT INTERLINKED
Interlinked is designed to be the most efficient and powerful system available in assisting its members in finding one another, building relationships and ultimately do business together. Interlinked is a private network and it is not open to the public. You must be invited or apply to be part of the community. Our proven process utilizes four primary systems: one, through our custom automated campaigns (IRocket), second through media InterlinkedTV, thirdly our Ideal room, fourth, through our relationships with strong partners and events. For more information go to http://www.interlinked.com.

Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Delray Wannemacher

James Czirr
Follow us on
Visit website